- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05332002
sFOLFOXIRI nel carcinoma gastroesofageo avanzato (SAGE)
Uno studio di fase II sulla sFOLFOXIRI nel carcinoma gastroesofageo avanzato (SAGE)
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The overall purpose of this protocol is to serve as a Single Arm Phase II trial of a four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor two (HER2) negative gastric and esophageal cancers (GEC). This study evaluates the hypothesis that the use of sFOLFOXIRI in gastroesophageal cancer (GEC) will increase response rates beyond that expected with FOLFOX, while maintaining acceptable tolerability. The primary endpoint of this study is the objective response rate (ORR) while the key secondary endpoints include the progression free survival (PFS), overall survival (OS), and adverse event (AE) rates. The goal of this study is to establish the activity level of sFOLFOXIRI, with the thought that this could be further developed in the metastatic and/or peri-operative space if a sufficiently interesting degree of efficacy is observed.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Patrick Boland, MD
- Numero di telefono: (732)235-2465
- Email: pb564@cinj.rutgers.edu
Luoghi di studio
-
-
New Jersey
-
Hamilton, New Jersey, Stati Uniti, 08690
- Reclutamento
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
Contatto:
- Patrick Boland, MD
-
Lakewood, New Jersey, Stati Uniti, 08701
- Reclutamento
- RWJBarnabas Health - Monmouth Medical Center Southern Campus
-
Contatto:
- Patrick Boland, MD
-
Long Branch, New Jersey, Stati Uniti, 07740
- Reclutamento
- RWJBarnabas Health - Monmouth Medical Center
-
Contatto:
- Patrick Boland, MD
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- Rutgers Cancer Institute of New Jersey
-
Contatto:
- Patrick Boland, MD
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
-
Contatto:
- Patrick Boland, MD
-
Newark, New Jersey, Stati Uniti, 07112
- Reclutamento
- RWJBarnabas Health - Newark Beth Israel Medical Center
-
Contatto:
- Patrick Boland, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Histologically and/or cytologically confirmed metastatic or unresectable adenocarcinoma of esophageal, gastroesophageal junction or gastric origin
-
Tumor is HER2 negative by standard local testing methodology
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2
-
Measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1
-
No prior systemic therapy for the present cancer given in the metastatic setting and > 6 months from administration of peri-operative chemotherapy, if applicable
o Note: up to two prior cycles of mFOLFOX6 for the present illness is permitted if patients otherwise qualify for the study with adequate baseline imaging
-
At least 18 years of age
-
Adequate bone marrow and organ functions as defined by:
-
Absolute neutrophil count ≥ 1500 cells/ μL
-
Hemoglobin ≥ 8 g/ dL
-
Platelets > 100,000 / μL
-
Creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault
-
Total bilirubin ≤ ULN
-
Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
-
Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately.
-
Ability to understand the nature of this study protocol and give written informed consent.
-
Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures.
Exclusion Criteria:
- Receipt of any investigational agents at the time of registration
- Known, untreated brain metastases
- Grade two or greater peripheral neuropathy
- Presence of any additional active malignancy within the past three years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
- For those patients who are going to receive nivolumab
- No active use of systemic corticosteroids at the time of enrollment, at a dose equivalent of 10 mg/day or prednisone
- Clinically significant autoimmune disease which is active or has required systemic immunosuppression within the last two years
- Prior organ transplant or bone marrow transplant
- History of interstitial lung disease or pneumonitis
- Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure, unstable angina or active arrhythmia
- Major surgery within the four weeks prior to initiation of study treatment
- A history of allergy or hypersensitivity to any of the study drugs
- Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: 4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),
A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:
|
This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC). The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Tassi di eventi avversi
Lasso di tempo: Tre anni
|
Tre anni
|
|
|
Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors ( RECIST) criteria version 1.1
Lasso di tempo: Three Years
|
To determine the clinical efficacy of treatment regimen in terms of objective response rate. |
Three Years
|
|
Progression Free Survival (PFS)
Lasso di tempo: Three Years
|
To determine the clinical efficacy of the study treatment in terms of progressive free survival. |
Three Years
|
|
Overall Survival (OS)
Lasso di tempo: Three Years
|
To determine the clinical efficacy of the study treatment in terms of overall survival. |
Three Years
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Patrick Boland, MD, Rutgers Cancer Institute of New Jersey
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 072204
- Pro2022000268 (Altro identificatore: Rutgers Cancer Institute of New Jersey)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .